Last September, Gilead made the unexpected move of launching authorized generics to its blockbuster hepatitis C drugs Epclusa and Harvoni, well before their patients expire. Now the copycats have ...

More than a decade ahead of their patents’ expiration dates, Gilead Sciences is releasing authorized generics of two of its hepatitis C drugs. The launch is planned to happen more than a decade ahead ...

The fun part about a programming language like C is that although the language doesn’t directly support many features including object-oriented programming and generics, there’s nothing that’s keeping ...

Gilead Sciences isn't letting a few of its own generics interfere with advertising its pan-genotypic hep C drug Epclusa. The Big Biotech is turning to TV again to promote its hep C franchise, this ...

Gilead Sciences will offer a cheaper version of its blockbuster hepatitis C drugs, Epclusa and Harvoni, which sparked controversy when they were initially introduced at a price of more than $1,000 per ...

Some Medicare Part D plans did not cover generic versions of pricey hepatitis C drugs in 2019, leaving millions in savings on the table, according to a new watchdog report. The report, released ...

Gilead Sciences' plan to sell lower-priced generic versions of chronic hepatitis C treatments Harvoni and Epclusa has raised provider hopes that the move will accelerate state efforts to improve ...